Comparative Pharmacology
Head-to-head clinical analysis: PENTACARINAT versus PENTAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENTACARINAT versus PENTAM.
PENTACARINAT vs PENTAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pentamidine is an antiprotozoal agent that interferes with the synthesis of nucleic acids and proteins, possibly through inhibition of dihydrofolate reductase and disruption of polyamine synthesis.
Pentamidine is an antiprotozoal agent that interferes with nucleotide and nucleic acid synthesis, possibly by binding to DNA and inhibiting RNA and protein synthesis. It also affects membrane integrity and inhibits oxidative phosphorylation.
4 mg/kg IV once daily for 21 days for Pneumocystis jirovecii pneumonia (PCP) treatment; 300 mg (or 4 mg/kg) via nebulizer once monthly for PCP prophylaxis.
4 mg/kg intravenously once daily for 21 days (Pneumocystis jirovecii pneumonia); or 300 mg deep intramuscularly every 3 weeks for prophylaxis.
None Documented
None Documented
Clinical Note
moderatePentamidine + Gatifloxacin
"Pentamidine may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderatePentamidine + Rosoxacin
"Pentamidine may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderatePentamidine + Trovafloxacin
"Pentamidine may increase the hypoglycemic activities of Trovafloxacin."
Clinical Note
moderatePentamidine + Nalidixic acid
"Pentamidine may increase the hypoglycemic activities of Nalidixic acid."
Terminal elimination half-life is 3-4 hours in patients with normal renal function, but can be prolonged to 18-24 hours in renal impairment.
Terminal elimination half-life: 6-24 hours (prolonged in renal impairment; up to 48 hours in anuria).
Renal: 10-20% unchanged; biliary/fecal: minimal; remainder metabolized.
Renal: approximately 60-70% unchanged; biliary/fecal: minimal, <10%.
Category C
Category C
Antiprotozoal Agent
Antiprotozoal Agent